{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095766","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.498267+00:00","generated_at":"2026-05-31T09:46:01.161662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR","bullets":["Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.","Cash, equivalents and marketable securities $220.4M expected to fund into H2 2026.","ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive gynecological cancer patients.","ACR-2316 WEE1/PKMYT1 inhibitor Phase 1 on track to start 4Q 2024.","Raised $130M in oversubscribed private placement financing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095766","json":"https://secwatch.observer/filing/0000950170-24-095766.json","markdown":"https://secwatch.observer/filing/0000950170-24-095766.md","text":"https://secwatch.observer/filing/0000950170-24-095766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/0000950170-24-095766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/acrv-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:46:01.161662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}